Determination of the primary molecular target of 1,2,4-triazole-ciprofloxacin hybrids

Molecules

Volumn 20, Issue 4, 2015, Pages 6254-6272

  Plech, Tomasz ^a   Kaproń, Barbara ^a   Paneth, Agata ^a   Kosikowska, Urszula ^a   Malm, Anna ^a   Strzelczyk, Aleksandra ^b   Stączek, Paweł ^b   ͆wiątek, Łukasz ^a   Rajtar, Barbara ^a   Polz Dacewicz, Małgorzata ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b UNIVERSITY OF LODZ   (Poland)

Author keywords

Fluoroquinolones; Gyrase DNA; MTT assay; Topoisomerase inhibitors; Topoisomerase IV

Indexed keywords

1,2,4-TRIAZOLE; ANTIINFECTIVE AGENT; CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING); GYRASE INHIBITOR; TRIAZOLE DERIVATIVE;

CHEMISTRY; DRUG EFFECTS; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEK293 CELL LINE; HUMAN; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ANTI-BACTERIAL AGENTS; CIPROFLOXACIN; DNA TOPOISOMERASES, TYPE II; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HEK293 CELLS; HUMANS; STRUCTURE-ACTIVITY RELATIONSHIP; TOPOISOMERASE II INHIBITORS; TRIAZOLES;

EID: 84946156549     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules20046254     Document Type: Article

References (15)

1. Oliphant, C.M.; Green, G.M. Quinolones: A comprehensive review. Am. Fam. Phys. 2002, 65, 455-464.
2. Sharma, P.C.; Jain, A.; Jain, S. Fluoroquinolone antibacterials: A review on chemistry, microbiology and therapeutic prospects. Acta Pol. Pharm. 2009, 66, 587-604.
3. Dalhoff, A. Global fluoroquinolone resistance epidemiology and implications for clinical use. Interdiscip. Perspect. Infect. Dis. 2012, 2012, 976273.
4. Goldstein, F.W.; Acar, J.F. Epidemiology of quinolone resistance: Europe and North and South America. Drugs 1995, 49, 36-42.
5. Redgrave, L.S.; Sutton, S.B.; Webber, M.A.; Piddock, L.J.V. Fluoroquinolone resistance: Mechanisms, impact on bacteria, and role in evolutionary success. Trends Microbiol. 2014, 22, 438-445.
6. Plech, T.; Wujec, M.; Kosikowska, U.; Malm, A.; Rajtar, B.; Polz-Dacewicz, M. Synthesis and in vitro activity of 1,2,4-triazole-ciprofloxacin hybrids against drug-susceptible and drug-resistant bacteria. Eur. J. Med. Chem. 2013, 60, 128-134.
7. Foroumadi, A.; Emami, S.; Hassanzadeh, A.; Rajaee, M.; Sokhanvar, K.; Moshafi, M.H.; Shafiee, A. Synthesis and antibacterial activity of N-(5-benzylthio-1,3,4-thiadiazol-2-yl) and N-(5-benzylsulfonyl-1,3,4-thiadiazol-2-yl)piperazinyl quinolone derivatives. Bioorg. Med. Chem. Lett. 2005, 15, 4488-4492.
8. Foroumadi, A.; Ghodsi, S.; Emami, S.; Najjari, S.; Samadi, N.; Faramarzi, M.H.; Beikmohammadi, L.; Shirazi, F.H.; Shafiee, A. Synthesis and antibacterial activity of new fluoroquinolones containing a substituted N-(phenethyl)piperazine moiety. Bioorg. Med. Chem. Lett. 2006, 16, 3499-3503.
9. Collin, F.; Karkare, S.; Maxwell, A. Exploiting bacterial DNA gyrase as a drug target: Current state and perspectives. Appl. Microbiol. Biotechnol. 2011, 92, 479-497.
10. Kotiranta, A.; Lounatmaa, K.; Haapasalo, M. Epidemiology and pathogenesis of Bacillus cereus infections. Microbes Infect. 2000, 2, 189-198.
11. Bottone, E.J. Bacillus cereus, a volatile human pathogen. Clin. Microbiol. Rev. 2010, 23, 382-398.
12. Kautzky, F.; Hartinger, A.; Köhler, L.D.; Vogt, H.-J. In vitro cytotoxicity of antimicrobial agents to human keratinocytes. J. Eur. Acad. Dermatol. Venereol. 1996, 6, 159-166.
13. Hoshino, K.; Kitamura, A.; Morrissey, I.; Sato, K.; Kato, J.; Ikeda, H. Comparison of inhibition of Escherichia coli topoisomerase IV by quinolones with DNA gyrase inhibition. Antimicrob. Agents Chemother. 1994, 38, 2623-2627.
14. Plech, T.; Paneth, A.; Kaproń, B.; Kosikowska, U.; Malm, A.; Strzelczyk, A.; Stączek, P. Structure-activity relationship studies of microbiologically active thiosemicarbazides derived from hydroxybenzoic acid hydrazides. Chem. Biol. Drug Des. 2015, 85, 315-325.
15. Takenouchi, T.; Munekata, E. Amyloid beta-peptide-induced inhibition of MTT reduction in PC12h and C1300 neuroblastoma cells: effect of nitroprusside. Peptides 1998, 19, 365-372.